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Progesterone receptor membrane components
Receptor regulation
A B S T R A C T
The classical steroid receptors (nuclear receptors), including those for progesterone (nPRs), are thoroughly
characterized. The knowledge about so-called non-genomic effects, which are mediated by extra-nuclear in-
itiated signals, has increased immensely the last decades. In a previous clinical study of endometrial hyperplasia,
we observed that the antiproliferative progestin effect persisted after 3 months treatment with levonorgestrel
(LNG) intrauterine system (IUS) even with a complete downregulation of nPRs. This raised the question of what
other mechanisms than signaling through nPRs could explain such an observation. In the present study, RT-qPCR
was employed to characterize mRNA expression for nPRs, membrane progesterone receptors (mPRs) and pro-
gesterone receptor membrane components (PGRMCs) in women (n = 42) with endometrial hyperplasia that
received intrauterine low dose LNG for 6 months. At the end of this period endometrial tissue showed that nPRs
were virtually completely downregulated (≈ 10 % of baseline) whereas the levels of remaining mPRs, subtype-
α, -β and -γ were 76 %, 59 % and 73 % of baseline, respectively. PGRMC1 was downregulated to 15 % of
baseline, in contrast to PGRMC2, which was upregulated to about 30 % above baseline. We used human cancer
cells from uterine cervix (C-4I cells) as control. Progesterone caused a concentration-dependent antiproliferative
effect but in several and separate studies, we were unable to detect nPRs (immunocytochemistry) in the C-4I
cells. The use of RT-qPCR showed that nPRs were undetectable in C-4I cells, in contrast to mPRs and PGRMCs
with a distinct mRNA expression. The present study suggests that mPRs and/or PGRMCs preserve the anti-
proliferative effect of LNG in the human endometrium and are responsible for the concentration-dependent
antiproliferative effect of progesterone in C-4I cells.
1. Introduction
Physiogical and pharmacological progesterone effects were known
long before the search for molecular mechanisms was initiated. The
identification of high affinity binding proteins (nPRs) in cytoplasm with
[3H]-progesterone was a breakthrough [1]. In the classical genomic
signaling pathway progesterone and other progestins bind to nPRs lo-
cated in the cytoplasm, which leads to a conformational change with
dissociation of heat shock proteins, dimerization, translocation to the
nucleus and binding to hormone responsive elements in target genes
[2]. However, other mechanisms of progesterone action have also been
reported, such as non-genomic effects due to the rapid onset [3]. The
knowledge about these extranuclear-initiated mechanisms gradually
emerged [4–7]. The discovery and characterization of membrane pro-
gesterone receptors (mPRs) [8,9]were important contribution to the
understanding of non-genomic effects.
One of the earliest recognized effects of steroid hormone action was
receptor down-regulation (including nPRs) in response to ligand
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binding [10]. However, limited information exists whether mPRs are
subject to downregulation as response to various signal molecules, in-
cluding hormones and drugs. In a clinical study of patients with levo-
norgestrel (LNG) intrauterine system (IUS) treatment of endometrial
hyperplasia, we observed a persistent antiproliferative endometrial ef-
fect even if nPRs were completely downregulated [11]. In studies of the
human cell line C-4I, derived from cervical cancer of the uterus [12],
progesterone inhibited growth in a concentration-dependent manner
[13,14]. Despite repeated analyses with immunocytochemistry, we
were unable to detect nPRs in the C-4I cells. The inhibitory constant
(IC50-value) of progesterone was 5.9 μM (recalculation based on raw
data) [13] and 2.1 μM [14]. These observations of progesterone effects
without presence of nPRs, suggested that non-genomic and receptor-
like mechanism were involved in the maintained antiproliferative effect
in patients with endometrial hyperplasia and the concentration-de-
pendent antiproliferative effects in the C-4I cells. In addition to mPRs,
PGRMCs were potential candidates for the non-genomic effects in
human endometrium and cells derived from a cancer of the uterine
cervix. PGRM1C and PGRMC2 belongs to a family of membrane-asso-
ciated progesterone receptors (MAPRs), also detected in the female
reproductive tract in humans [15]. In the present work, we tested
whether mPRs and /or PGRMCs were present in the endometrium after
LNG-IUS therapy with downregulated nPRs [11], and if mPRs and /or
PGRMCs were present in the C-4I cells with undetectable protein ex-
pression of nPRs [13,14]. Gene expression (mRNA of nPRs, mPRS and
PCRMCs) was employed as surrogate markers for protein expression of
receptors / membrane components.
2. Materials and methods
2.1. Clinical study design
A group of 61 women were recruited to a prospective, multicenter
pilot study to assess the efficacy of LNG-IUS 13.5 mg (Jaydess™, Bayer
Pharmaceuticals, Berlin, Germany) for treatment of endometrial hy-
perplasia [16,17]. Only those women (n = 49) with a completed
treatment period of six months were included in the presented study.
2.2. Study subjects
All women had consulted their gynecologists due to abnormal
uterine bleeding. Prior to study inclusion they underwent a clinical
examination. Endometrial biopsies were obtained for histopathological
diagnosis, D-score [18] and RT-PCR analysis. In seven of the 49 women,
endometrial biopsy material was insufficient for qPCR analysis. Table 1
shows the characteristics of the 42 women. Histopathological material
from the endometrium was obtained prior to study inclusion (baseline
biopsy) and after completing LNG-IUS therapy (post therapy biopsy).
Therapy response in post therapy biopsy was defined as ordinary pro-
liferative endometrium or endometrium with progestin effect (gland-
ular atrophy and pseudo-decidualization of the stromal cells).
2.3. Handling of tissue and cells, and analytical details
Details about a) Endometrial biopsies, b) C4-I cell culture and cell
sampling, and c)Tissue and cell preservation awaiting analysis, d) RNA
isolation and cDNA synthesis, e)Analysis of reference gene stability, f)
Selection of primers and reaction efficiency and g)Quantitative real-
time PCR are presented in [19].
3. Results
3.1. Endometrial samples - nPRs, mPRs and PGRMCs
Maintained exposure of LNG to the endometrium caused a profound
effect on the mRNA expression of classical progesterone receptors. After
6 months with low dosage LNG-IUS (Jaydess™ treatment the nPRB
(p < 0.001) and nPRA + nPRB (p < 0.001) were almost completely
downregulated with approximately 10 % receptor mRNA detectable
compared to the baseline values (Table 2).
LNG administration did also cause downregulation of mPRs but
markedly less compared with nPRs (Table 2). The remaining receptor
subpopulations after LNG-administration were 76 %, 73 % and 59 % of
baseline values for mPRα, mPRγ and mPRβ, respectively. Only the re-
duction of mPRβ expression was statistically different from baseline
values (p < 0.02). The mRNA expression of PGRMCs was also influ-
enced during the LNG treatment (Table 2). The expression of PGRMC1
Table 1
Demographic and histopathological characteristics of the women (n = 42) with
endometrial hyperplasia included in the study. Menopausal status was defined
according to s-estradiol (nmol/l) and s-FSH (IU/l).
Characteristics Median (25; 75
percentile)
Range
Age (years) 49 (43.8; 53.3) 30−84
Weight (kg) 75 (68.8; 87.0) 56−120
Height (cm) 167 (161; 170) 149−176














(estradiol ≥ 0.12, FSH ≤ 30)
Perimenopausal
(estradiol ≥ 0.12. FSH > 30)
Postmenopausal
















































* WHO classification, [44].
** D-score category was missing for one patient.
Table 2
Expression (mRNA) of nuclear progesterone receptors, membrane progesterone
receptors and progesterone receptor membrane components in the en-
dometrium, before (baseline) and after 6 months LNG (levonorgestrel) in-
trauterine treatment. Statistical significance was evaluated by Wicoxon signed
rank test with P < 0.05 as the significance limit (Sigmaplot™). Data presented
as median and 25; 75 percentiles. The data are presented as CNRQ (Calibrated
Normalized Relative Quantity).
Genes Baseline biopsy Post therapy biopsy p-value
nPRB 3.255 (1.315;4.965) 0.290 (0.290; 0188) < 0.001
nPRA + nPRB 3.45 (2.16;4.94) 0.39 (0.23;071) < 0.001
mPRα 1.09 (0.72;1.78) 0.83 (0.59;1.71) n.s.
mPRβ 1.24 (0.91;1.88) 0.73 (0.43;1.24) < 0.02
mPRγ 1.25 (0.56;2.11) 0.91 (0.49;1.39) n.s.
PGRMC1 2.59 (1.59;3.45) 0.40 (0.25;0.72) < 0.001
PGRMC2 0.84 (0.71;1.17) 1.10 (0.72; 1.63) n.s.
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was reduced significantly to 15 % of baseline levels, whereas PGRM2
increased with about 30 % above baseline levels. Fig. 1 shows the re-
lative effect of continued LNG exposure on endometrial progesterone
receptors and membrane components.
3.2. C-4I cells - nPRs, mPRs and PGRMCs
The human cervical cancer cell line (C-4I) was employed in the
present study as a control. The absence of nPR expression was con-
firmed with RT- qPCR technology. Table 3 shows that mRNA for the
mPRs and PGRMCs was expressed during logarithmic growth.
4. Discussion
Progesterone modulates gene expression via classical nPRs and
causes rapid effects via mPRs and the less characterized PGRMCs. In
receptor pharmacology desensitization is a well-known phenomenon
wherein continued exposure to an agonist (hormone, neurotransmitter
or drug) results in reduced tissue response. At least two mechanisms
may cause this process: Receptor downregulation and uncoupling be-
tween receptor and effector component(s). One of the earliest re-
cognized effects of steroid hormone action was receptor down-
regulation in response to ligand binding [10]. In a previous study, we
found that endometrial nPRs were completely downregulated after 3
months treatment with LNG-IUS (Mirena™) releasing ≈ 20 μg/day, in
women diagnosed with endometrial hyperplasia [11]. The mechanism
behind this ligand-dependent down-regulation involves phosphoryla-
tion of nPRs by p42yp44 MAPKs at serine-294, thus targeting nPRs for
ubiquitination and destruction by the 26S proteasome [20]. In two
more recent studies the treatment period was extended to six months
and the dose was reduced with LNG-IUS (Jaydess™), releasing ≈ 10 μg/
day [16,17]. Endometrial biopsies were obtained prior to and after
LNG-IUS therapy.
The biopsy material of the present study was analyzed with qPCR
technology to determine the mRNA expression of the genes encoding
for nPRs, mPRs and PGRMCs. However, the observed changes in mRNA
can, but may not, reflect expression of the respective proteins.
Occurrence of translational and posttranslational modification may
exist. Examples of this are modified protein folding and glycosylation
patterns. This demands caution in the phenotypic interpretation of
changes in mRNA levels.
An increased ratio between nPRB and nPRA stimulates of growth in
endometrial cancers [21,22]. In the present study, the endometrial
expression of nPRs was reduced to 10 % or less of baseline values. It is
possible that the mechanism behind the clinical effect of LNG-IUS
therapy (antiproliferative effect), is the removal of functional nPRB
receptors in the endometrium. Since some categories of endometrial
hyperplasia may represent preliminary stages of endometrial cancer
[23], the present study implies that maintained progestin therapy may
prevent the development of malignancy.
The relative binding affinities of LNG and progesterone are 100 %
and 50 %, respectively, above the reference steroid for nPR, prome-
gestone (R5020) [24]. The high LNG affinity for nPRs, in addition to
persistent high local LNG concentration in the endometrium observed
with IUS in situ [25], suggest that the downregulation of nuclear re-
ceptors was initiated and maintained by LNG.
However, LNG-IUS may also modify mPRs activity indirectly by
reducing the serum progesterone levels due to suppression of ovulation.
In a study that comprised 27 fertile regularly menstruating women,
serum samples were obtained in the mid-luteal phase without and after
3 months with LNG-IUS in situ. Progesterone levels showed a significant
fall from 32.8 to 8.4 nanomol/L in serum [26].
The discovery of mPRs can account for at least some of the extra-
nuclear-initiated (non-genomic) effects. They were described as pro-
teins with seven transmembrane domains, G-protein-coupled with in-
hibition of adenylate cyclase activity [9]. Subsequent studies indicated
that the mPRs did not belong to the GPCR superfamily but to the PAQR
(progesterone and adipoQ receptors) subfamily [27,28]. Furthermore,
neither the cellular localization(s) nor the effector mechanism(s) have
been settled; for review see: [29].
In human endometrium the post-ovulatory rise in progesterone co-
incided with a significant induction of mPRα and a gradual down-
regulation of mPRγ [27] and represents physiological receptor regula-
tion. The present study shows a pharmacological effect on the mPR
mRNA expression. Downregulation was observed for the three in-
vestigated mPRS sdubtypes, but with a dissimilar magnitude. The me-
chanisms behind the downregulation of mPRs are not clarified but
evidence for a receptor endocytosis via a clathrin-mediated pathway
have been presented [30]. While LNG has high affinity for nPRs [24],
norgestrel (the racemic mixture of LNG and the inactive dextroisomer)
has no or very low affinity for human mPRα [28,31]. This is a strong
argument against a direct role of LNG in the downregulation of mPRs.
It appears that mPRs have significant roles in premalignant and
malignant diseases of the female genital tract. These receptors have
been detected in the cervical cancer cell lines HeLa [32] and C4-I
(present report), in diverse epithelial human ovarian cancer biopsies
[33] and in commonly used ovarian cancer cell lines [34]. Endometrial
cancer showed decreased expression of mPRα and mPRβ, but unaltered
expression of mPRγ in endometrial cancer compared to control tissue
[35].
In addition to mPRs we considered PGRM1C and PGRMC2 as po-
tential candidates responsible for the non-genomic gestagen-induced
antiprolifrative effect in the endometrium and in the C-4I cells. These
two small proteins belong to a family with four members of membrane-
associated progesterone receptors (MAPRs). The cloning of PGRMC1
(designated HPR6) and PGRMC2 (designated Dg6) was published in
Fig. 1. Regulation of endometrial nPRs, mPRs and PGRMCs by levonorgestrel
IUS. The gene expression (mRNA) after 6 months is presented as % of baseline
values. The analytical equipment and experimental methods are described in
[19].
Table 3
Expression (mRNA) of nuclear progesterone receptors, membrane progesterone
receptors and progesterone receptor membrane components in human cancer
cells of the uterine cervix (C-4I cells, ATCC® CRL-1594™). The data are pre-
sented as CNRQ (Calibrated Normalized Relative Quantity).
Receptor type Detected Mean ± SD Minimum Maximum
nPRB No
PRA+/nPRB No
mPRα Yes 1.000 ± 0.290 0.790 1.495
mPRβ Yes 1.016 ± 0.218 0.782 1.301
mPRγ Yes 1.008 ± 0.034 0.962 1.033
PGRMC1 Yes 1.016 ± 0.200 0.778 1.252
PGRMC2 Yes 1.008 ± 0.144 0.864 1.199
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1998 [36]. Ten years thereafter, a review summed up the accumulated
knowledge on PGRMC1 biology [37]. PGRMC1 is a transmembrane
protein, predominantly located in intracellular membranes, but has also
been reported to be present at the plasma membrane ectoside in some
cell types. The protein is not a progesterone receptor but a component
of a multi-functional complex with partners dependent on the cell type.
PGRMC1 is involved in regulation of cytochrome P450, steroidogenesis
and vesicle trafficking, binding of steroids and other hydrophobic mo-
lecules, cell cycle regulation and many other processes, for review see
[38]. In this context, the idea that PGRMC1 is responsible for the cell
surface localization of mPRα is exciting [39].
PGRMC1 plays an important role in the antiapoptotic action of
progesterone [40]. The significant reduction in endometrial mRNA
expression observed in the present study may antagonize PGRMC1′s
antiapoptotic effect. This is compatible with the normalization of the
hyperplastic endometrium. The possibility exists that PGRMC1 may be
a useful biomarker for successful LNG therapy with reversal of malig-
nant development. This idea is in agreement with the reported upre-
gulation of PGRMC1 in a number of cancer types including those of the
female genital tract [41].
PGRMC2 has many similarities with PRGMC1. Both are composed of
a single amino acid chain, have a ubiquitous expression with mainly
intracellular localization, expressed in human female reproductive tis-
sues and upregulated by progesterone [15]. However, the functional
role of PGRMC2 is less characterized than that of PGRMC1 [42], but is
probably a signal adapter protein with some functions that makes it
distinguishable from PGRMC1 such as binding to CYP21A2 and
CYP3A4 [43]. In SKOV-3 ovarian cancer cells PGRMC2, but not
PGRMC1, inhibited cell migration whereas no differences were evident
with regard to cell viability or response to cisplatin and progesterone
[43]. It is suggested that PGRMC2 plays a role in tumor suppression and
not, as PGRMC1, in tumor promotion [42]. The present study showed a
striking difference in mRNA expression with an opposite modulation of
the proteins. PGRMC1was significantly downregulated whereas
PGRMC2 was moderately upregulated. Thus, it is tempting to suggest
that PGRMC2 has an essential role in the suppression of the abnormal
growth typical for endometrial hyperplasia.
The cell line C-4I with undetectable nPRs (immunohistochemistry),
was included into this study as a systemic control. The present results
without detectable mRNA expression of nPRs are in agreement with our
previous observations. However, the C-4I cells showed distinct mRNA
expression for mPRs and PGMRCs during logarithmic growth. We be-
lieve that progesterone signaling through mPRs and/or PGRMCs ex-
plains the concentration-dependent antiproliferative effect of proges-
terone in C-4I cells [13,14]. Based on the knowledge that PGRMC2 is
involved in tumor suppression, it is possible that PGRMC2 coordinates
the signals responsible for the antiproliferative effect of progesterone in
C-4I cells. Under the given conditions in the present study, absence of
nPRn was a common feature for the endometrium and the C-4I cells.
However, the respective mechanism was entirely different with LNG-
induced downregulation for the endometrium and the genetic makeup
for C-4I cells. PGRMC2 might be the common link in the anti-
proliferative effect of gestagens, observed in the present study.
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